As reported in the media this week, the Senate Economics Legislation Committee discussed the administration of the R&D Tax Incentive. Swanson Reed has reviewed the discussion in detail. It involved interactions between three people, whose comments are summarised and paraphrased below: Greens Senator Barbara Pocock: Had queries around how many reviews are conducted each year; Queried whether staff conducting reviews include personnel with Science and Engineering qualifications; Asked for details of fines or penalties for incorrect claims, and indicated concerns that possible penalties […]
Over recent months, a number of companies have reported to the ASX receipt of substantial Refundable R&D Tax Offsets. Notable receipts include: Recce Pharmaceuticals (ASX: RCE) received $5.34 M related to its anti-infective platform; Race Oncology (ASX:RAC) received $2.8M related to its cancer treatments; Ecograf (ASX: EGR) received $1.7M related to its EcoGraf HFfree proprietary purification technology; Chimeric Therapeutics (ASX: CHM) received $4.5M related to its cancer treatments; Elixir Energy (ASX: EXR) received $3.8M related to its unconventional gas project […]
Some key events impacting Australia’s R&D Tax Incentive over the past 12 months during calendar year 2025 included: The release of proposed legislation to exclude gambling and tobacco companies from eligibility under the R&D Tax Incentive; The strategic examination and review of Australia’s Research and Development (R&D) system progressed and released a discussion paper on R&D Incentives that contained some significant potential changes for consideration. Swanson Reed made a submission to both the general review and the discussion paper on R&D Incentives; A new R&D Tax Incentive registration […]
Industry Innovation and Science Australia (IISA) is the federal government department responsible for determining whether companies’ activities meet the legislative criteria eligible under the R&D Tax Incentive. The 2025 Annual Report for IISA was recently released, and a section of the report provides an update on Legal matters and litigation relevant to the department. Litigation on R&D activity now usually starts in the The Administrative Review Tribunal of Australia (ART), rather than Administrative Appeals Tribunal (AAT). However, this change is not likely […]